📍 Whitefield, Bangalore
HOD & Senior Consultant · Surgical Oncology
Consultation by Appointment
Home/Cancer Specialties/Thoracic Cancer
Cancer Specialties

Thoracic Cancer Surgery

Surgical pathways for selected lung and chest-wall malignancies, planned in coordination with pulmonology and oncology teams.
Lung Resection
Minimally Invasive Surgery
Multidisciplinary Planning
Robotic Surgery

How your treatment is personalised

Every treatment plan is personalised. Dr Ashwin K.R. reviews your scans, pathology and, where relevant, biomarker results with a multidisciplinary team, then recommends a sequence of treatment that fits your cancer and your health.

  • Your case is reviewed at a multidisciplinary tumour board.
  • Surgery, systemic treatment and radiotherapy are explained with their goals and side effects.
  • A second opinion is welcome, and you can bring your reports to the consultation.

Looking for more detail? Read our complete guide with 49 patient FAQs: Thoracic Cancer Treatment FAQs.

Overview

Thoracic Cancer Surgery is one of Dr Ashwin K.R.’s core areas of practice at Aster Whitefield, Bangalore. Treatment planning combines careful staging, multidisciplinary discussion and a surgical approach chosen to balance oncological safety with quality of life.

Symptoms & When to See a Surgeon

  • Persistent cough, chest pain or breathlessness
  • Coughing up blood
  • Unexplained weight loss with respiratory symptoms
  • An abnormal finding on chest imaging
These symptoms have many possible causes, but persistent or unexplained symptoms warrant a timely surgical oncology consultation.

Surgical Treatment Approach

  • Careful staging with imaging and, where indicated, biopsy
  • Minimally invasive and robotic-assisted thoracic resections where suitable
  • Multidisciplinary discussion involving pulmonology and oncology
  • Clear discussion of recovery and lung function after surgery
Where relevant, this may draw on Robotic Cancer Surgery → as part of an integrated treatment plan.

Why Choose Dr Ashwin K.R.

16+ years of experience, 11,000+ major cancer surgeries and a practice built on clear communication — every patient understands their diagnosis, options and the realistic road ahead before deciding on surgery.

Quick facts

Experience
16+ years
Hospital
Aster Whitefield
Location
Whitefield, Bangalore
Approach
Multidisciplinary

Have reports for a thoracic cancer diagnosis?

Bring your pathology and imaging reports for a focused surgical opinion.

Recovery and what to bring to your consultation

  • Recovery depends on the treatment you need. Your team will explain the expected hospital stay, return to daily activities and follow-up before any treatment starts.
  • Bring your pathology and imaging reports, any blood test results, a list of current medicines, summaries of any earlier treatment, and your ID and insurance documents.

Frequently Asked Questions

1. Understanding Your Thoracic Cancer Diagnosis

Is lung cancer curable?

Lung cancer can be cured in many patients when it is found at an early stage, and even advanced lung cancer can now often be controlled for years with targeted therapy and immunotherapy.

Your chance of cure depends on:

  • The type of lung cancer (non-small cell or small cell)
  • The stage – especially whether lymph nodes or distant organs are involved
  • Biomarkers such as EGFR, ALK or PD-L1
  • Your lung function, fitness and other health conditions

What the evidence shows:

  • Stage I non-small cell lung cancer: surgery or stereotactic radiation (SBRT) is associated with high cure rates.
  • Stage II–III: combined treatment (surgery, chemotherapy, immunotherapy, radiation) can cure a meaningful proportion of patients.
  • Stage IV: cure is uncommon, but many patients – particularly those with targetable mutations or high PD-L1 – can live for several years with good quality of life.

What is thoracic cancer?

Thoracic cancer is any cancer that starts in the chest, including the lungs, the esophagus (food pipe), the pleura (lining of the lungs), the thymus, the trachea and the chest wall.

  • Lung cancer is by far the most common thoracic cancer.
  • Each type behaves differently and needs a different treatment approach.
  • Care is typically led by a thoracic oncology team, including a thoracic surgeon, medical oncologist and radiation oncologist.

What are the different types of lung cancer and other thoracic cancers?

The main types of thoracic cancer are non-small cell lung cancer, small cell lung cancer, esophageal cancer, pleural mesothelioma and thymic tumors, with lung carcinoids and other rare tumors making up the rest.

Table 1. Types of thoracic cancer at a glance

Type of CancerWhere It StartsKey Facts
Non-small cell lung cancer (NSCLC)Lung tissueAbout 85% of lung cancers; includes adenocarcinoma (most common, including in non-smokers), squamous cell and large cell carcinoma
Small cell lung cancer (SCLC)Central airways of the lungAbout 10–15% of lung cancers; grows quickly, strongly linked to smoking, often responds well to initial chemotherapy
Lung carcinoid (neuroendocrine) tumorHormone-producing cells of the airwaysUsually slow-growing; frequently curable with surgery
Esophageal cancerFood pipeSquamous cell carcinoma is more common in Asia; adenocarcinoma is linked to chronic acid reflux and Barrett's esophagus
Pleural mesotheliomaLining around the lungsStrongly linked to past asbestos exposure, often decades earlier
Thymoma and thymic carcinomaThymus gland, behind the breastboneRare; thymoma may be associated with myasthenia gravis
Lung metastasesCancer that has spread to the lungs from another organTreated according to the original (primary) cancer

I never smoked. Why do I have lung cancer?

Lung cancer can develop in people who have never smoked; an estimated 10–25% of lung cancers worldwide occur in never-smokers, and the proportion is higher in parts of Asia.

Known causes in never-smokers include:

  • Second-hand smoke
  • Radon gas in homes and buildings
  • Outdoor air pollution and indoor smoke from cooking fuels
  • Occupational exposure (asbestos, silica, diesel exhaust, certain metals)
  • Previous chest radiation
  • Family history and inherited susceptibility
  • Acquired gene changes such as EGFR or ALK, which are more common in never-smokers

Why this matters:

  • Lung cancers in never-smokers more often carry targetable mutations (EGFR, ALK, ROS1).
  • Comprehensive biomarker testing is therefore especially important.
  • A positive result may open the door to targeted tablets instead of, or before, chemotherapy.

How quickly do I need to start treatment?

Most patients begin thoracic cancer treatment within about two to six weeks of diagnosis, a timeframe generally considered appropriate for completing staging, biomarker testing and treatment planning.

  • Waiting for biomarker results often leads to a better-matched treatment for advanced lung cancer.
  • Small cell lung cancer grows faster and usually needs treatment to start sooner.
  • Your team will tell you if your situation needs urgent action.

Situations that may need urgent treatment:

  • Coughing up large amounts of blood
  • Severe breathlessness or a large fluid build-up around the lung
  • Facial and arm swelling (superior vena cava obstruction)
  • Inability to swallow liquids
  • Signs of spinal cord compression or brain metastases

Table 2. Typical timeline from diagnosis to treatment

StepWhat HappensTypical Timeframe*
1. First specialist consultationHistory, examination, review of CT scans and reportsWithin 1 week of referral
2. Staging testsPET-CT, brain MRI, lung function tests1–2 weeks
3. BiopsyBronchoscopy, EBUS, CT-guided or endoscopic biopsyWithin 1–2 weeks
4. Pathology and biomarkersCancer type, PD-L1, gene mutation testing3–7 working days (pathology); 1–3 weeks (genomics)
5. Tumor board discussionMultidisciplinary team recommends a planWithin about 1 week of results
6. Treatment beginsSurgery, radiation, chemotherapy, targeted therapy or immunotherapyAbout 2–6 weeks from diagnosis

*Timeframes vary with your cancer, test availability and personal circumstances.

Should I get a second opinion for lung cancer or thoracic cancer?

A second opinion is a normal, widely accepted part of cancer care, and most oncologists welcome it.

A second opinion is especially useful when:

  • You are told your cancer is inoperable
  • Surgery would involve removing a whole lung or the esophagus
  • Biomarker testing has not been fully done
  • The cancer is rare, such as mesothelioma or thymic carcinoma

Bring these to your second-opinion appointment:

  • CT and PET-CT images (CD or link) and reports
  • Pathology report and biopsy blocks or slides
  • Biomarker / molecular test reports
  • Lung function test results and a list of medicines

2. Survival Rates, Staging and Prognosis

What is the survival rate for lung cancer and other thoracic cancers?

Five-year survival for thoracic cancer depends heavily on stage: it ranges from well over half of patients for early-stage non-small cell lung cancer to under 10% for many cancers that have spread to distant organs.

  • The figures below are approximate U.S. population data (SEER) for patients diagnosed in past years.
  • They do not reflect the newest targeted therapies and immunotherapies, which have improved outcomes, particularly for advanced lung cancer.
  • They describe large groups of people, not any one individual.

Table 3. Approximate five-year relative survival by stage

Cancer TypeLocalizedRegional (nearby spread)Distant (spread far)All Stages
Non-small cell lung cancer~65%~37%~9%~28%
Small cell lung cancer~30%~18%~3%~7%
Lung carcinoid tumor~97%~87%~58%~89%
Esophageal cancer~49%~28%~6%~22%
Pleural mesothelioma~18%~12%~10%~12%

Source: rounded approximations of U.S. SEER / American Cancer Society five-year relative survival, for general education only. Your oncologist can explain your individual outlook.

How long can I live with stage 4 lung cancer?

Survival with stage 4 lung cancer has improved substantially, and many patients now live for several years, particularly those whose tumors have a targetable mutation or respond to immunotherapy.

  • EGFR- or ALK-positive lung cancer: targeted tablets can control the cancer for years in many patients; in recent trials, median survival has been measured in years rather than months.
  • High PD-L1 tumors: immunotherapy can produce long-lasting responses in a proportion of patients, some of whom remain in remission years later.
  • Oligometastatic disease (a few spots of spread): surgery or SBRT to all sites, combined with systemic therapy, may give long-term control in selected patients.
  • Supportive and palliative care alongside treatment has been shown to improve symptoms and quality of life.

Your oncologist can give you a more personal estimate based on your biomarkers, fitness and response to treatment.

What stage is my lung cancer and what does it mean?

Your stage describes the size of the tumor and how far it has spread, and it is one of the most important factors in choosing treatment and estimating prognosis.

  • Non-small cell lung cancer, esophageal cancer and mesothelioma are staged with the TNM system: T (tumor size), N (lymph nodes), M (metastasis).
  • The TNM categories combine into stages I to IV, each with sub-stages (e.g. IA, IIIB).
  • Small cell lung cancer is also commonly described as limited stage (confined to one side of the chest and treatable in one radiation field) or extensive stage (spread more widely).

Table 4. Lung cancer stages explained

StageGeneral MeaningTypical Treatment Approach
Stage ISmall tumor confined to the lung, no lymph node spreadSurgery (lobectomy or segmentectomy) or SBRT if surgery is not suitable
Stage IILarger tumor or spread to lymph nodes within the lungSurgery with chemotherapy and/or immunotherapy before or after; targeted therapy after surgery for EGFR/ALK-positive tumors
Stage IIISpread to lymph nodes in the center of the chest (mediastinum) or tumor invading nearby structuresChemoradiation followed by immunotherapy, or chemo-immunotherapy followed by surgery in selected patients
Stage IVSpread to the other lung, fluid around the lung or heart, or distant organs (brain, bone, liver, adrenal)Targeted therapy, immunotherapy and/or chemotherapy; radiation or surgery for selected sites

What factors affect my prognosis?

Prognosis is shaped by the stage, type and biomarker profile of your cancer, your lung function and overall fitness, and how well the cancer responds to treatment.

  • Stage at diagnosis – one of the strongest factors.
  • Cancer type – carcinoids and thymomas generally carry a better outlook than small cell lung cancer or mesothelioma.
  • Biomarkers – EGFR, ALK, ROS1 and other targetable mutations, and PD-L1 level.
  • Performance status – how active you are day to day.
  • Lung and heart function – these influence which treatments are possible.
  • Smoking status – stopping smoking improves treatment tolerance and outcomes.
  • Specialist care – treatment by high-volume thoracic teams is associated with better surgical outcomes.

3. Symptoms and Warning Signs of Thoracic Cancer

What are the early warning signs of lung cancer?

Common warning signs of lung cancer include a cough that does not go away, coughing up blood, breathlessness, chest pain and unexplained weight loss; any of these lasting more than three weeks should be checked by a doctor.

Table 5. Common symptoms by thoracic cancer type

Cancer TypeCommon Symptoms
Lung cancerPersistent or changing cough, coughing up blood, breathlessness, chest or shoulder pain, hoarseness, repeated chest infections, fatigue, weight loss, finger clubbing
Esophageal cancerDifficulty swallowing (food sticking), pain on swallowing, unintentional weight loss, heartburn or indigestion that is new or persistent, vomiting, hoarseness
Pleural mesotheliomaBreathlessness from fluid around the lung, chest wall pain, fatigue, night sweats, weight loss
Thymic tumorsChest pressure, cough, breathlessness; muscle weakness, drooping eyelids or double vision if linked with myasthenia gravis
Advanced spreadBone pain, headaches or seizures, jaundice, swelling of the face and neck

Early lung cancer often causes no symptoms. Many of these symptoms are more often caused by non-cancerous conditions, but they should still be assessed.

Is coughing up blood always a sign of lung cancer?

No, but coughing up blood (hemoptysis) is not considered normal and should be evaluated promptly, especially in current or former smokers over 40.

  • Common non-cancer causes include chest infections, bronchitis, bronchiectasis and tuberculosis.
  • A chest X-ray and, often, a CT scan are the usual first tests.
  • Bronchoscopy may be recommended if the scan is unclear or bleeding continues.
  • Large amounts of blood (more than a few teaspoons) need emergency care.

Why is lung cancer often found late?

Lung cancer is often found late because the lungs have few pain nerves and early tumors rarely cause symptoms, so symptoms often appear only once the cancer has grown or spread.

  • Early symptoms such as cough or breathlessness are easily blamed on smoking, infection or ageing.
  • Low-dose CT screening for high-risk people can detect lung cancer at an earlier, more curable stage.
  • Many early cancers are found incidentally on scans done for other reasons.

Next step: if you are a current or former heavy smoker, ask your doctor whether you qualify for lung cancer screening.

When should I see a doctor urgently about chest symptoms?

See a doctor promptly for a cough lasting more than three weeks, coughing up blood, or difficulty swallowing, and seek emergency care for heavy bleeding, severe breathlessness or chest pain.

Table 6. How urgently to seek care

SymptomAction
Coughing up more than a few teaspoons of bloodGo to emergency care
Severe or sudden breathlessness, or chest painGo to emergency care
Swelling of the face, neck and arms with visible chest veinsGo to emergency care
New weakness or numbness in the legs, or loss of bladder controlGo to emergency care
Unable to swallow liquids or salivaSeek same-day medical care
Any amount of blood in phlegmBook a doctor's appointment within days
Cough, hoarseness or swallowing difficulty lasting more than 3 weeksBook a doctor's appointment
Unexplained weight lossBook a doctor's appointment

4. Diagnosis, Biopsy and Biomarker Testing

What tests will I need to diagnose and stage thoracic cancer?

Thoracic cancer is confirmed by examining a tissue or fluid sample under the microscope, and scans, endoscopy and lung function tests are used to determine the stage and plan treatment.

Table 7. Diagnostic and staging tests for thoracic cancer

TestPurpose
Chest X-rayOften the first test; may show a mass or fluid
Contrast CT scan of chest and abdomenShows tumor size, lymph nodes and spread to the liver or adrenal glands
PET-CT scanDetects active cancer in lymph nodes, bones and other organs; key for staging before surgery or radiation
MRI brainChecks for brain metastases, which may not cause symptoms
Bronchoscopy (including navigational / robotic bronchoscopy)Camera into the airways to inspect and take biopsies
EBUS-TBNA (endobronchial ultrasound)Samples lymph nodes in the center of the chest through the airway, without surgery
CT-guided needle biopsySamples a lung nodule through the chest wall
Upper GI endoscopy and endoscopic ultrasound (EUS)Diagnoses and stages esophageal cancer
Pleural tap (thoracentesis) or thoracoscopySamples fluid or lining of the lung; key for mesothelioma
Pulmonary function tests and cardiac testsHelp estimate whether surgery or radiation is likely to be well tolerated
Molecular and PD-L1 testingIdentifies targeted therapy and immunotherapy options

Is a lung biopsy risky, and can it spread the cancer?

Lung biopsies are generally well tolerated, and the risk of a biopsy spreading cancer is very low; the information gained is needed to choose the right treatment.

  • CT-guided biopsy: the most common side effect is a small air leak (pneumothorax); many resolve on their own, and a minority need a small chest drain.
  • Bronchoscopy and EBUS: usually done under sedation as a day procedure; minor bleeding or sore throat may occur.
  • Coughing up a small amount of blood after biopsy is common and usually settles quickly.
  • Your team chooses the most suitable route based on where the tumor and lymph nodes are.

Table 8. What to expect on the day of a biopsy

ProcedureAnesthesiaProcedure TimeFasting*Usually Home
CT-guided lung biopsyLocal anesthetic ± mild sedation30–60 minutes4–6 hoursSame day, after 2–4 hours' observation and a chest X-ray
Bronchoscopy / EBUS-TBNASedation or general anesthesia30–60 minutes6 hoursSame day
Navigational / robotic bronchoscopyGeneral anesthesia45–90 minutes6 hoursSame day
Upper GI endoscopy / EUSSedation15–45 minutes6 hoursSame day
Pleural tap (thoracentesis)Local anesthetic15–30 minutesUsually noneSame day
Medical thoracoscopy / VATS biopsySedation or general anesthesia30–60 minutes6 hours1–3 days (chest drain)

*Follow the exact fasting and blood-thinner instructions given by your team. A responsible adult should take you home after sedation.

What is biomarker testing for lung cancer, and why is it so important?

Biomarker (molecular) testing looks for specific gene changes and proteins in lung cancer, and international guidelines recommend it for advanced non-small cell lung cancer because it can identify targeted tablets or immunotherapy that may work better than chemotherapy alone.

Table 9. Key biomarkers in non-small cell lung cancer

BiomarkerHow Common (approx.)Examples of Matched Treatment
EGFR mutationAbout 10–15% in Western patients; considerably higher (up to around 30–50%) in Asian patients and never-smokers with adenocarcinomaOsimertinib; amivantamab-based combinations
ALK rearrangementAbout 3–7%, more often in younger never-smokersAlectinib, lorlatinib, brigatinib
ROS1 rearrangementAbout 1–2%Crizotinib, entrectinib, repotrectinib
KRAS G12C mutationAbout 10–13% of adenocarcinomas, mainly in smokersSotorasib, adagrasib
BRAF V600E mutationAbout 1–2%Dabrafenib + trametinib
MET exon 14 skippingAbout 3–4%Capmatinib, tepotinib
RET fusionAbout 1–2%Selpercatinib, pralsetinib
HER2 mutationAbout 2–4%Trastuzumab deruxtecan
NTRK fusionUnder 1%Larotrectinib, entrectinib
PD-L1 expressionVaries; about 30% have high (≥50%) expressionGuides immunotherapy choice
  • Liquid biopsy (a blood test for tumor DNA) can find mutations when tissue is limited or to speed up results.
  • Esophageal cancer may also be tested for HER2, PD-L1, MMR/MSI and claudin 18.2.
  • Availability and approvals of these drugs vary by country.

How long does it take to get my biopsy and biomarker results?

Most biopsy results are available within about 3 to 7 working days, while comprehensive gene testing (next-generation sequencing) usually takes 1 to 3 weeks.

Table 10. Typical test result turnaround times

TestTypical Turnaround*Can Treatment Start Before Results?
CT / PET-CT / MRI reportSame day to 2 daysNot applicable
Biopsy (histopathology)3–7 working daysNo – diagnosis must be confirmed first
PD-L1 (immunohistochemistry)3–7 working daysUsually waited for in advanced NSCLC
Single-gene tests (EGFR PCR, ALK IHC)3–7 working daysUsually waited for in advanced NSCLC
Next-generation sequencing (NGS) on tissue1–3 weeksOften waited for unless symptoms are urgent
Liquid biopsy (blood NGS)About 1–2 weeksCan run in parallel with tissue testing

*Turnaround times vary between laboratories.

5. Thoracic Cancer Treatment Options

What is the best treatment for my lung cancer?

The most suitable treatment depends on the type, stage and biomarker profile of your cancer and your fitness, and it is recommended by a multidisciplinary thoracic tumor board.

Table 11. Main treatments by thoracic cancer type and stage

Cancer TypeEarly / LocalizedLocally AdvancedMetastatic
NSCLCLobectomy or segmentectomy; SBRT if not fit for surgeryChemo-immunotherapy then surgery, or chemoradiation then durvalumabTargeted therapy if a driver mutation is found; otherwise immunotherapy ± chemotherapy
SCLCSurgery for very small tumors (rare), then chemotherapyChemotherapy with concurrent radiation (limited stage)Chemotherapy plus immunotherapy (extensive stage)
Lung carcinoidSurgerySurgery with lymph node removalSomatostatin analogues, targeted therapy, PRRT
Esophageal cancerEndoscopic resection for very early tumors; esophagectomyChemoradiation or perioperative chemotherapy, then esophagectomy; definitive chemoradiation for someChemotherapy with immunotherapy and/or HER2-targeted therapy
Pleural mesotheliomaSurgery (pleurectomy/decortication) within multimodality treatment in selected patientsImmunotherapy or chemotherapy ± surgeryNivolumab + ipilimumab, or chemotherapy ± immunotherapy
Thymoma / thymic carcinomaThymectomySurgery ± radiation; chemotherapy to shrink first if neededChemotherapy; targeted therapy in selected cases

Table 12. How long does lung cancer treatment take? Typical pathways

Treatment PathwayActive Treatment PhaseAdditional / Maintenance PhaseApproximate Total Duration*
Stage I – surgerySurgery with 2–4 day hospital stayNone for most patientsAbout 1–2 months including recovery
Stage I – SBRT1–8 sessions over 1–2 weeksNoneAbout 2 weeks
Stage II–III – chemo-immunotherapy, then surgery3–4 cycles over 9–12 weeks, then surgeryImmunotherapy after surgery in some patients, up to about 1 yearAbout 4–15 months
Stage II–III EGFR-positive – surgery, then targeted therapySurgery ± chemotherapy (about 3 months)Osimertinib tablets for 3 yearsAbout 3–3½ years
Stage III – chemoradiationDaily radiation with chemotherapy over about 6 weeksDurvalumab every 2–4 weeks for up to 12 monthsAbout 13–14 months
Stage IV – targeted therapyDaily tabletsContinued while effective and toleratedOngoing
Stage IV – chemo-immunotherapy4 cycles over about 12 weeksMaintenance immunotherapy ± pemetrexed, up to about 2 yearsUp to about 2 years

*Durations are typical examples from current standard pathways and vary with response, side effects and individual plans.

Will I need surgery for lung cancer, and what type?

Surgery offers one of the best chances of cure for many early-stage lung cancers and is usually recommended when the tumor can be fully removed and your lung function allows it.

Table 13. Types of thoracic cancer surgery

ProcedureWhat Is RemovedCommonly Used For
LobectomyOne lobe of the lung (the right lung has 3, the left has 2)Standard operation for most early NSCLC
SegmentectomyOne or more anatomical segments of a lobeSmall (about 2 cm or less) peripheral tumors; patients with limited lung function
Wedge resectionA small wedge of lung around the tumorSmall nodules, carcinoids, metastases, or patients unfit for larger surgery
Sleeve lobectomyA lobe plus a section of airway, which is rejoinedCentral tumors, to avoid removing the whole lung
PneumonectomyThe entire lungLarge central tumors when lesser surgery is not possible
EsophagectomyPart of the esophagus, reconstructed using the stomachEsophageal cancer
ThymectomyThe thymus gland and surrounding fatThymoma and thymic carcinoma
Pleurectomy / decorticationThe lining of the lung and chest wallSelected pleural mesothelioma

Table 14. Preparing for lung cancer surgery: timeline checklist

WhenWhat to Do*
As soon as surgery is plannedStop smoking; start walking and breathing exercises (prehabilitation); ask about pulmonary rehabilitation
2–3 weeks beforePre-operative assessment: blood tests, ECG, lung function tests; review of all medicines
About 5–7 days beforeStop or adjust blood thinners and certain diabetes or herbal medicines – only as instructed by your team
Night beforeFast as instructed (usually no food for 6 hours and clear fluids until 2 hours before)
Day of surgeryBring your medicines list, reports and comfortable clothing; arrange someone to take you home on discharge

*Always follow your own surgical team's instructions, which may differ.

Is robotic or keyhole (VATS) lung surgery an option for me?

Robotic-assisted and VATS (video-assisted thoracoscopic) surgery are now widely used for most early-stage lung cancer operations, offering faster recovery with cancer outcomes comparable to open surgery in large studies.

Potential benefits:

  • Small incisions instead of a large chest opening (thoracotomy)
  • Less pain and lower need for strong pain medication
  • Shorter hospital stay, often 2–4 days
  • Faster return to daily activities
  • Fewer complications such as pneumonia in many studies

Note: Some large or central tumors, or tumors invading the chest wall or major vessels, may still require open surgery. Your surgeon will advise the most suitable approach.

Can I live normally with part of my lung removed?

Many people live active, independent lives after lung cancer surgery, because the remaining lung tissue usually provides enough breathing capacity for everyday activities.

  • Before surgery, lung function tests (FEV1, DLCO) and sometimes an exercise test help estimate whether you are likely to have enough lung reserve.
  • After lobectomy, most people notice some breathlessness on heavy exertion at first, which often improves over months.
  • Pulmonary rehabilitation and regular exercise can help you regain strength and stamina.
  • After pneumonectomy, adjustment takes longer and strenuous activity may remain limited.

Table 15. Typical hospital stay and recovery after thoracic surgery

SurgeryHospital Stay*Light ActivityReturn to Desk Work*Driving*
Robotic / VATS lobectomy or segmentectomy2–4 daysWithin 1 week3–6 weeksAbout 2–4 weeks
Open lobectomy (thoracotomy)4–7 days1–2 weeks6–12 weeks4–6 weeks
Pneumonectomy5–10 days2–3 weeks2–3 months4–6 weeks
Esophagectomy7–14 days2–4 weeks2–3 months4–8 weeks
Robotic / VATS thymectomy1–3 daysWithin 1 week2–4 weeksAbout 2 weeks

*Recovery varies with the extent of surgery, your fitness and any complications. Drive only when you can turn and brake comfortably and are not taking sedating pain medication.

Table 16. Typical recovery milestones after robotic / VATS lung surgery

MilestoneTypical Timing*
Sitting out of bed and walkingDay of surgery or day 1
Chest drain removedDay 1–3 (later if there is an air leak)
Discharge homeDay 2–4
Wound check and pathology results1–2 weeks after surgery
Avoid heavy lifting (over about 5 kg)4–6 weeks
Start of additional treatment (if needed)Usually 4–8 weeks after surgery
Near-normal energy levels1–3 months

*Milestones vary between individuals.

What is SBRT, and is it as good as surgery for early lung cancer?

SBRT (stereotactic body radiotherapy) delivers very precise, high-dose radiation in a few sessions and is a standard, effective treatment for early-stage lung cancer in people who cannot have or do not want surgery.

  • Treatment usually involves 1 to 8 sessions over 1–2 weeks, with no incision or hospital stay.
  • Published studies report high rates of local tumor control for small tumors.
  • Side effects are usually mild: tiredness, chest wall soreness or a mild cough.
  • For patients fit for surgery, surgery remains the standard; trials comparing the two directly are ongoing.
  • SBRT is also used for a limited number of metastases (oligometastatic disease).

What radiation treatments are used for thoracic cancer?

Radiation therapy is used with curative intent for early lung cancer, to treat locally advanced lung and esophageal cancer together with chemotherapy, and to relieve symptoms when cancer has spread.

Table 17. Radiation treatment types and schedules

TypeUsed ForTypical Schedule
SBRT / SABREarly lung cancer; limited metastases1–8 sessions over 1–2 weeks
Chemoradiation (IMRT / VMAT / IGRT)Stage III NSCLC; limited-stage SCLC; esophageal cancerAbout 25–33 daily sessions, 5 days a week, over 5–6½ weeks
Pre-operative chemoradiationEsophageal cancer before esophagectomyAbout 23 sessions over 5 weeks, with weekly chemotherapy
Stereotactic radiosurgery (SRS)Small brain metastases1–5 sessions
Palliative radiationBone pain, bleeding, airway blockage1–10 sessions
Proton therapy (selected centers)Selected cases where sparing the heart or lungs is criticalSimilar to conventional schedules
  • Each daily session usually takes 15–30 minutes, most of it for positioning.
  • After chemoradiation for stage III NSCLC, consolidation immunotherapy (durvalumab) for up to 12 months has been shown to improve survival.

Will I need chemotherapy, and how is it given?

Chemotherapy is used for many thoracic cancers – before or after surgery, together with radiation, or in combination with immunotherapy for advanced disease – and is usually given as day-care infusions every three weeks.

Table 18. Common systemic treatment schedules at a glance

TreatmentUsed ForHow OftenTypical CourseSetting / Time per Visit
Platinum doublet chemotherapy (e.g. carboplatin/cisplatin + pemetrexed or paclitaxel)NSCLC, mesotheliomaEvery 3 weeks4 cycles (about 12 weeks), sometimes followed by maintenanceDay care; about 3–5 hours
Carboplatin/cisplatin + etoposide + immunotherapyExtensive-stage SCLCEvery 3 weeks4 cycles, then immunotherapy maintenanceDay care; 3 consecutive days of etoposide
Chemo-immunotherapy before surgeryStage II–III NSCLCEvery 3 weeks3–4 cycles before surgeryDay care; about 3–5 hours
Weekly carboplatin + paclitaxel with radiationEsophageal cancerWeekly5 weeksDay care; about 2–3 hours
FLOT chemotherapyEsophageal / GE junction adenocarcinomaEvery 2 weeks4 cycles before and 4 after surgeryDay care with 24-hour infusion pump at home
Immunotherapy alone (pembrolizumab, nivolumab, atezolizumab, durvalumab)NSCLC, SCLC, esophageal cancer, mesotheliomaEvery 2–6 weeksUp to about 1–2 years, depending on settingDay care; about 30–60 minutes
Targeted tablets (e.g. osimertinib, alectinib)Biomarker-positive NSCLCDaily at homeAs long as effective in advanced disease; 3 years after surgery for someMonthly or quarterly review

Schedules are typical examples. Your regimen may differ based on your cancer, blood counts and tolerance.

What is targeted therapy for lung cancer, and will it work for me?

Targeted therapy uses drugs, usually daily tablets, that block a specific gene change driving the cancer; for patients whose tumors carry that change, trials have shown it is often more effective and better tolerated than chemotherapy.

  • It only works if your tumor has the target, which is why comprehensive biomarker testing comes first.
  • EGFR-positive lung cancer: osimertinib is a standard first-line treatment and is also used after surgery to reduce the risk of recurrence.
  • ALK-positive lung cancer: alectinib or lorlatinib have controlled disease for several years in many trial patients and have good activity in the brain.
  • Resistance can develop over time; a repeat biopsy or liquid biopsy may identify the next treatment.
  • Common side effects include skin rash, diarrhea, nail changes and, less commonly, lung inflammation.

Is immunotherapy effective for lung cancer and other thoracic cancers?

Immunotherapy is a standard treatment for many lung cancers, esophageal cancers and mesotheliomas, and in a proportion of patients it produces responses that last for years.

  • NSCLC: used alone for high PD-L1 tumors, with chemotherapy for others, before and/or after surgery, and after chemoradiation for stage III.
  • SCLC: atezolizumab or durvalumab added to chemotherapy has been shown to improve survival in extensive-stage disease; durvalumab after chemoradiation has shown benefit in limited-stage disease.
  • Esophageal cancer: nivolumab after surgery for residual disease, and immunotherapy with chemotherapy for advanced disease.
  • Mesothelioma: nivolumab plus ipilimumab has been shown to improve survival, especially for non-epithelioid types.
  • Side effects: immune-related inflammation of the thyroid, skin, bowel, lungs or liver – report new symptoms promptly.

What are the treatment options for esophageal cancer?

Esophageal cancer is usually treated with chemotherapy or chemoradiation followed by surgery when the cancer is localized, while very early tumors may be removed endoscopically and advanced cancers are treated with systemic therapy.

  • Very early tumors: endoscopic mucosal resection or submucosal dissection, without major surgery.
  • Localized tumors: pre-operative chemoradiation or perioperative chemotherapy, then esophagectomy (often minimally invasive or robotic).
  • Squamous cell cancers: definitive chemoradiation without surgery may be an option for some patients.
  • Nutrition support: a feeding tube or stent may be used temporarily to maintain nutrition if swallowing is difficult.
  • Advanced disease: chemotherapy with immunotherapy and/or HER2- or claudin 18.2-targeted therapy.

Table 19. Typical esophageal cancer treatment timeline (localized disease)

PhaseWhat HappensTypical Duration*
Staging and planningEndoscopy, EUS, PET-CT, nutrition assessment, tumor board2–4 weeks
Pre-operative treatmentChemoradiation (about 5 weeks) or FLOT chemotherapy (4 cycles, about 8 weeks)5–8 weeks
Recovery and re-stagingRest, nutrition support, repeat PET-CTAbout 6–10 weeks
EsophagectomySurgery and hospital stay7–14 days in hospital
Post-operative treatmentImmunotherapy (nivolumab) for residual disease, or 4 further FLOT cyclesAbout 2 months to 1 year
Full recovery of eating and energySmall frequent meals, dietitian follow-up3–6 months or longer

*Typical examples; your pathway may differ.

How is pleural mesothelioma treated?

Pleural mesothelioma is usually treated with immunotherapy or chemotherapy, with surgery and radiation offered to carefully selected patients as part of a multimodality plan at specialist centers.

  • Nivolumab + ipilimumab or platinum-pemetrexed chemotherapy (with or without immunotherapy) are standard first-line options.
  • Pleurectomy/decortication may be considered for selected patients with epithelioid disease.
  • Fluid control: an indwelling pleural catheter or talc pleurodesis can often relieve breathlessness.
  • Clinical trials are an important option given the rarity of the disease.

What is a tumor board, and who will be on my thoracic cancer care team?

A thoracic tumor board is a meeting where specialists from each relevant field review your case together to agree on a recommended treatment plan.

  • Thoracic surgeon
  • Medical oncologist
  • Radiation oncologist
  • Pulmonologist and interventional pulmonologist
  • Radiologist and nuclear medicine specialist
  • Pathologist and molecular pathologist
  • Gastroenterologist (for esophageal cancer)
  • Oncology nurse navigator, dietitian, physiotherapist, psycho-oncologist and palliative care team

Can I join a clinical trial for lung cancer?

Clinical trials offer access to promising new treatments and may be a suitable option at many stages of thoracic cancer.

  • Trials are carefully regulated and ethically reviewed.
  • Participants generally receive at least the current standard of care.
  • You can withdraw at any time.
  • Ask whether any trials match your cancer type, stage and biomarkers, especially if your cancer has a rare mutation or has progressed.

6. Side Effects and Managing Treatment

What side effects should I expect from thoracic cancer treatment?

Side effects depend on the treatment you receive; many are temporary, and most can be reduced with modern supportive care.

Table 20. Common side effects and how they are managed

TreatmentCommon Side EffectsHow They Are Managed
Lung surgeryPain, breathlessness, air leak, chest infection, fatigue, numbness around the scarPain relief, breathing exercises, early walking, physiotherapy
EsophagectomyDifficulty eating large meals, reflux, weight loss, dumping syndromeSmall frequent meals, dietitian support, sleeping propped up
ChemotherapyFatigue, nausea, low blood counts and infection risk, hair loss (with some drugs), neuropathyAnti-nausea medicines, growth factor injections, dose adjustments
Chest radiationFatigue, painful swallowing (esophagitis), skin redness, coughPain relief, soft diet, skin care
Radiation pneumonitis (weeks to months later)Cough, breathlessness, low feverSteroids; early reporting is important
Targeted therapySkin rash, diarrhea, nail infections, liver changes, swellingSkin care, antidiarrheals, dose adjustment
ImmunotherapyFatigue, rash, thyroid problems, colitis, pneumonitis, hepatitisEarly reporting, steroids or hormone replacement as needed

Will I lose my hair during lung cancer treatment?

Hair loss depends on the drugs used: paclitaxel and etoposide commonly cause hair loss, while pemetrexed, carboplatin alone, immunotherapy and most targeted tablets usually do not.

  • Hair thinning, if it occurs, usually starts 2–3 weeks after the first cycle.
  • Regrowth usually begins within 1–3 months after finishing.
  • Some targeted therapies change hair texture or cause eyelash growth.
  • Chest radiation does not cause hair loss on the head.

How can I manage breathlessness, cough and fatigue?

Breathlessness, cough and fatigue are common with thoracic cancer, and each can often be eased with a combination of medical treatment and practical self-care.

  • Breathlessness: your team will treat the cause where possible (fluid, infection, anemia, airway blockage); use breathing techniques, a hand-held fan and pacing; oxygen if your levels are low.
  • Fluid around the lung: drainage, talc pleurodesis or an indwelling pleural catheter can often bring rapid relief (see table below).
  • Cough: cough suppressants, inhalers or treating infection; radiation or airway procedures for tumors blocking airways.
  • Fatigue: research shows regular light exercise can reduce cancer-related fatigue; balance activity with rest.
  • Pulmonary rehabilitation can improve stamina before and after treatment.

Table 21. Options for draining fluid around the lung (pleural effusion)

ProcedureWhat It InvolvesHospital Stay*Best Suited For
Pleural tap (thoracentesis)Needle drainage of fluid under local anestheticSame dayQuick relief; fluid may return
Indwelling pleural catheter (IPC)Thin tube left in place; fluid drained at home, often 2–3 times a weekDay procedureRecurrent fluid; avoiding hospital stays
Talc pleurodesisTalc used to seal the space around the lung, via chest drain or thoracoscopyAbout 2–5 daysRecurrent fluid when the lung fully re-expands

*Stays vary with your condition.

When should I call my oncology team immediately?

Contact your oncology team immediately, day or night, if you develop a temperature of 38°C (100.4°F) or above during chemotherapy, or sudden worsening of breathing.

Table 22. When to contact your care team

SymptomThresholdAction
Fever or chills38.0°C (100.4°F) or above, or shiveringCall immediately / go to emergency
BreathlessnessSudden or rapidly worsening, or at restGo to emergency care
Coughing up bloodMore than a few teaspoonsGo to emergency care
Chest painNew, severe or with breathlessnessGo to emergency care
New cough with fever on immunotherapy or after radiationAnyCall the same day (possible pneumonitis)
DiarrheaMore than 4–6 episodes a day above normal, or bloodyCall the same day
Unable to swallow fluidsFor 12–24 hoursCall the same day
Leg pain or swellingOne leg red, painful or swollenCall the same day (possible blood clot)
Confusion, severe headache, seizure or new weaknessAny new episodeGo to emergency care

Follow any specific thresholds your own team gives you. +91 88840 09955

7. Smoking, Breathing, Nutrition and Daily Life

Should I stop smoking now that I have lung cancer?

Yes. Stopping smoking after a lung cancer diagnosis is one of the most beneficial steps you can take, and quitting is worthwhile at any stage of treatment.

  • May improve how well radiation and chemotherapy work.
  • Is associated with fewer surgical complications such as pneumonia and poor wound healing.
  • Is associated with longer survival and a lower risk of a second lung cancer.
  • Can improve breathing, energy and appetite.
  • Nicotine replacement, medications and counselling together substantially increase the chance of quitting successfully – ask your team for referral.

Table 23. Stop-smoking support options

OptionHow It Is UsedTypical Duration*
Nicotine replacement (patch, gum, lozenge)Patch for steady levels plus a fast-acting form for cravings8–12 weeks
Varenicline (prescription tablet)Start 1–2 weeks before your quit date12 weeks, sometimes longer
Bupropion (prescription tablet)Start 1–2 weeks before your quit date7–12 weeks
Counselling / quitline supportIndividual, group or telephone sessionsSeveral sessions over weeks to months

*Your doctor will check which options are suitable alongside your cancer treatment.

Can I exercise during and after lung cancer treatment?

Most people are encouraged to stay physically active during and after thoracic cancer treatment, adjusting intensity to how they feel and to their team's advice.

  • Before surgery (prehabilitation): walking and breathing exercises can improve fitness and recovery.
  • After surgery: start with short walks the day after surgery and build up gradually.
  • During chemotherapy or radiation: light to moderate activity, such as 20–30 minutes of walking most days.
  • Long term: aim for 150 minutes of moderate activity a week plus strength exercises twice a week, as able.
  • Avoid heavy lifting for about 4–6 weeks after chest surgery.

What should I eat if I have trouble swallowing or am losing weight?

Maintaining nutrition is very important during thoracic cancer treatment, and a cancer dietitian can tailor a plan when swallowing is difficult or weight is falling.

  • Eat small, frequent, high-protein, high-calorie meals and snacks.
  • Choose soft, moist foods; blend or puree if needed.
  • Use oral nutritional supplements if advised.
  • Sit upright during and for 30 minutes after meals.
  • A temporary feeding tube or esophageal stent may be recommended if you cannot eat enough by mouth.
  • Report weight loss of more than 5% of your body weight in a month.

Can I fly or travel during lung cancer treatment?

Many patients can travel during thoracic cancer treatment, but flying soon after lung surgery or with low oxygen levels requires medical clearance.

  • Air travel is usually avoided for about 2–4 weeks after lung surgery and until any air leak has resolved.
  • Patients with breathlessness may need an oxygen assessment before flying.
  • Plan travel around treatment cycles and blood count low points.
  • Carry a summary of your diagnosis, treatment and medicines.

8. Risk Factors, Genetics and Lung Cancer Screening

What causes lung cancer and other thoracic cancers?

Smoking is the leading cause of lung cancer, but radon, air pollution, asbestos and other exposures, as well as inherited and acquired gene changes, also contribute.

Table 24. Main risk factors by thoracic cancer type

Cancer TypeMain Risk Factors
Lung cancerTobacco smoking (including bidis and second-hand smoke), radon, air pollution, indoor biomass smoke, asbestos, silica, previous chest radiation, family history, prior tuberculosis or lung scarring
Esophageal squamous cell carcinomaTobacco (smoked and chewed), alcohol, very hot beverages, nutritional deficiencies
Esophageal adenocarcinomaChronic acid reflux (GERD), Barrett's esophagus, obesity, smoking
Pleural mesotheliomaAsbestos exposure, often 20–50 years before diagnosis; prior radiation; rarely inherited BAP1 mutation
Thymic tumorsNo clear lifestyle cause identified

Is lung cancer hereditary? Should my family be tested?

Most lung cancers are not inherited, but having a close relative with lung cancer modestly increases risk, and a small number of thoracic cancers are linked to inherited gene mutations.

  • The EGFR, ALK and similar mutations found in tumors are usually acquired, not inherited, so they are generally not passed on to children.
  • Rare inherited mutations (for example germline EGFR T790M or BAP1) may be suspected when several relatives are affected; genetic counselling is recommended in these cases.
  • Family members who smoke should be encouraged to quit and check whether they qualify for lung cancer screening.

Who should get lung cancer screening, and how is it done?

Annual low-dose CT (LDCT) screening is recommended for people at high risk of lung cancer, and in large trials it reduced lung cancer deaths by around 20–24%.

Table 25. Lung cancer screening eligibility (U.S. USPSTF guidance)

CriterionRecommendation
Age50–80 years
Smoking historyAt least 20 pack-years (e.g. 1 pack a day for 20 years)
Smoking statusCurrently smoking or quit within the past 15 years
TestLow-dose CT scan of the chest, once a year
Scan timeUnder 1 minute of scanning; no injection needed
  • Screening criteria differ between countries; some programmes also consider other risk factors.
  • Screening can find benign nodules that need follow-up scans; your doctor will explain the benefits and possible harms.

Table 26. Understanding your screening CT result (Lung-RADS categories)

CategoryWhat It MeansTypical Next Step*
1 – NegativeNo nodules or definitely benign findingsRepeat low-dose CT in 12 months
2 – Benign appearanceNodules very unlikely to be cancerRepeat low-dose CT in 12 months
3 – Probably benignLow likelihood of cancerLow-dose CT in 6 months
4A – SuspiciousModerate likelihood of cancerLow-dose CT in 3 months; PET-CT may be considered
4B / 4X – Very suspiciousHigher likelihood of cancerDiagnostic CT, PET-CT and/or biopsy, with specialist referral

*Based on the American College of Radiology Lung-RADS system; your doctor will tailor follow-up to your scan.

9. Life After Treatment: Follow-Up and Recurrence

What are the chances my lung cancer will come back?

The risk of recurrence depends on stage and type: it is lower for stage I cancers and higher for stage II–III and small cell lung cancer, which is why regular follow-up scans are important.

  • Most recurrences occur within the first two to three years after treatment.
  • Treatments given after surgery – chemotherapy, immunotherapy or targeted therapy (e.g. osimertinib for EGFR-positive cancer) – have been shown in trials to reduce the risk of recurrence.
  • People treated for lung cancer also have a higher risk of a new, second lung cancer, especially if they continue smoking.

What will my follow-up care look like after treatment?

Follow-up care involves regular check-ups and chest CT scans, most frequently in the first two to three years after treatment when recurrence risk is highest.

Table 27. Typical follow-up schedule after curative treatment

Time Since TreatmentTypical Visit FrequencyWhat Is Checked
Years 1–2Every 3–6 monthsSymptoms, examination, chest CT scan, side effect management
Year 3Every 6 monthsExamination and chest CT scan
Years 4–5Every 6–12 monthsExamination and chest CT scan
After 5 yearsOnce a yearLow-dose chest CT, smoking cessation support, survivorship care
  • Brain MRI or PET-CT is usually arranged only if symptoms or test results suggest a problem.
  • Report new symptoms such as persistent cough, bone pain or headaches between visits.

What happens if my lung cancer comes back or spreads?

Recurrent or metastatic lung cancer can often still be treated, and many patients have several lines of effective therapy available.

  • Local recurrence: may be treated with surgery, SBRT or chemoradiation, sometimes with curative intent.
  • A few metastases: SBRT or surgery to each site plus systemic therapy in selected patients.
  • Widespread disease: targeted therapy, immunotherapy, chemotherapy, antibody-drug conjugates or clinical trials.
  • Repeat biopsy may reveal a new target or resistance mechanism.
  • Palliative care helps control breathlessness, pain and other symptoms alongside active treatment.

10. Emotional Support, Practical Concerns and Next Steps

How do I cope emotionally with a lung cancer diagnosis?

Feeling shocked, frightened, angry or guilty after a thoracic cancer diagnosis is common and understandable, and professional emotional support is an important part of cancer care.

  • Talk to a psycho-oncologist, counsellor or psychologist experienced in cancer care.
  • Anyone with lungs can develop lung cancer; whatever your smoking history, you deserve compassionate, non-judgemental care.
  • Join a lung or thoracic cancer support group, in person or online.
  • Bring a trusted person to appointments to listen and take notes.
  • Tell your team about persistent low mood, anxiety or poor sleep; these can be treated.

Can I continue working during thoracic cancer treatment?

Many people continue working during treatment, often with adjusted hours or duties, although most need time off after surgery.

Table 28. Planning work around treatment

Treatment PhaseTypical Impact on Work*
Robotic / VATS lung surgery3–6 weeks off
Open lung surgery or esophagectomy6 weeks to 3 months off
Chemotherapy every 3 weeksOften most tired for 3–7 days after each cycle; many work part-time
Daily chemoradiation (5–6 weeks)Daily visits; fatigue and swallowing discomfort build toward the end – many take time off
SBRT (1–8 sessions)Usually minimal time off
Targeted tablets or immunotherapyMost people can work normally

*Individual experiences vary.

How much does thoracic cancer treatment cost, and will insurance cover it?

The cost of thoracic cancer treatment varies widely with the type of surgery, radiation and drugs used, and many health insurance plans cover a large part of it.

  • Personalised cost estimate from our financial counsellors
  • Help with insurance pre-authorisation and cashless claims
  • Guidance on government schemes and patient assistance programmes for targeted and immunotherapy drugs
  • [Add your hospital's insurance partners and financial assistance details here.]

Table 29. Cost estimate overview (to be completed by hospital)

TreatmentEstimated Cost RangeTypically Covered by Insurance?
Robotic / VATS lobectomy[range][Yes / Partial]
Esophagectomy[range][ ]
SBRT (full course)[range][ ]
Chemoradiation (full course)[range][ ]
Chemotherapy (per cycle)[range][ ]
Targeted therapy / immunotherapy (per month)[range][ ]

What questions should I ask my oncologist at my first appointment?

Preparing a list of questions before your first appointment helps you understand your diagnosis and take an active part in treatment decisions.

  • What type of thoracic cancer do I have, and what is the exact subtype?
  • What is the stage, and has it spread to lymph nodes, the brain or other organs?
  • Has my tumor been tested for all relevant biomarkers, including EGFR, ALK, ROS1, KRAS and PD-L1?
  • Is surgery possible? If not, why not?
  • What treatment do you recommend, and what are the alternatives?
  • What is the goal of treatment: cure, long-term control or symptom relief?
  • What side effects should I expect, and how will they be managed?
  • How will treatment affect my breathing, eating and daily activities?
  • Am I eligible for any clinical trials?
  • How long will treatment take, and how will it affect my work?
  • Who do I contact with questions or in an emergency?
  • What is the likely cost, and what support is available?

Table 30. What to bring to your first appointment

ItemWhy It Helps
Referral letter and prior consultation notesGives the team your full history
CT / PET-CT / MRI images (CD or link) and reportsAvoids unnecessary repeat scans
Pathology report and biopsy blocks / slidesAllows review and additional biomarker testing
Biomarker and PD-L1 reportsGuides treatment choice
Lung function tests and recent blood resultsHelps assess fitness for treatment
List of current medicines, inhalers and allergiesHelps your team avoid drug interactions and allergic reactions
Insurance card and IDSpeeds up registration and pre-authorisation
A family member or friendHelps with listening, notes and support

Why Choose Our Thoracic Cancer Center?

At Aster Whitefield Hospital, patients with lung, esophageal and other chest cancers can access:

  • Regular thoracic tumor board review of new cases [confirm frequency]
  • Robotic and VATS lung, esophageal and thymic surgery
  • EBUS, navigational bronchoscopy and interventional pulmonology
  • SBRT, IMRT and image-guided radiation therapy
  • Comprehensive biomarker testing and precision oncology
  • Access to targeted therapy, immunotherapy and clinical trials
  • Smoking cessation, pulmonary rehabilitation, nutrition, psycho-oncology and palliative care support

Book a consultation with a thoracic oncology specialist. Call +91 88840 09955 or /contact/ to schedule an appointment or request a second opinion.

Medical disclaimer – please note:

  • This information is for general education and does not replace professional medical advice.
  • Survival statistics, timelines, costs and treatment options are general and may not apply to your situation.
  • Drug availability and regulatory approvals vary by country.
  • Always consult your treating oncologist about your diagnosis and care.

Medical review and sources

Medically reviewed by Dr Ashwin K.R. · Last reviewed: 10 October 2026

  • National Comprehensive Cancer Network (NCCN) Guidelines: Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma
  • European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for lung cancer

Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified doctor about your specific diagnosis and treatment.